Tempus Labs

Tempus Labs is an AI-driven bioinformatics company with a proprietary data platform that delivers insights to improve clinical decisions and enable precision medicine in oncology, neurology, psychiatry, and infectious diseases. The company analyzes fragmented genetic and clinical data using machine learning and has gathered data from over 6 million patient records as of March 2023, claiming to have the world's largest library of clinical and molecular data.

Tempus operates three main business lines: gene sequencing and profiling, where it offers a range of DNA and RNA sequencing tests that can be ordered by healthcare providers and analyzed together with clinical data to provide therapeutic insights based on molecular profiles; data licensing, where it monetizes data using image recognition and NLP tools and licenses structured, anonymized data to pharmas via its Lens Platform to identify biomarkers and develop targeted drugs; and clinical trial matching, where its proprietary software notifies oncologists and patients of relevant precision medicine trials.

In June 2023 , Tempus launched Tempus One, an AI-enabled clinical assistant that provides patient insights through the Tempus desktop and mobile app. By unlocking clinical and genomic data power through AI, Tempus delivers precision medicine tools.

Key customers and partnerships

Tempus partners with pharmaceutical companies to enable therapeutic discovery and development through its data platform. In 2022, it partnered with Kartos on a companion diagnostic and inked a USD 70 million, 3-year drug discovery deal with GSK. In 2023, Tempus partnered with Acuatate to identify patient biomarker profiles for Acuatate 's elraglusib, collaborated with TScan on a companion diagnostic for TCR cancer therapies, and worked with AstraZeneca on an NSCLC trial to create a dataset for biomarkers and precision medicine. 

In November 2023, the company teamed up with pharmaceutical company Bristol Myers Squibb for strategic cancer research, which aimed to identify and validate new drug targets using multimodal datasets, computational approaches, and disease models derived from patients.

Funding and financials

The company’s latest funding round took place in October 2022, when it raised USD 100 million in equity financing from existing investors and USD 175 million in debt financing from funds managed by Ares Management. The new funds were allocated towards scaling its operations and building capabilities on its AI-enabled platform.